The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Abdelwahab, Mohammed G ^a   Fenton, Kathryn E ^a   Preul, Mark C ^a   Rho, Jong M ^a,d   Lynch, Andrew ^b   Stafford, Phillip ^c   Scheck, Adrienne C ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Nutricia Advanced Medical Nutrition   (United Kingdom)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; GLUCOSE; KETONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL METABOLISM; CONTROLLED STUDY; GLIOBLASTOMA; GLUCOSE BLOOD LEVEL; HISTOLOGY; HOMEOSTASIS; IN VIVO STUDY; KETOACIDOSIS; KETOGENIC DIET; MOUSE; NONHUMAN; SURVIVAL TIME; TUMOR CELL; TUMOR REGRESSION; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; BLOOD; BRAIN; C57BL MOUSE; CANCER TRANSPLANTATION; DIET THERAPY; DISEASE MODEL; GLIOMA; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TIME;

ANIMALIA; MUS;

3-HYDROXYBUTYRIC ACID; ANIMALS; BLOOD GLUCOSE; BRAIN; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KETOGENIC DIET; KETONES; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; TIME FACTORS;

EID: 84860521413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036197     Document Type: Article

References (38)

1. Ruggiero A, Cefalo G, Garre ML, Massimino M, Colosimo C, et al. (2006) Phase II trial of temozolomide in children with recurrent high-grade glioma. J Neurooncol 77: 89-94.
2. Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, et al. (2011) Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38: 243-253.
3. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, et al. (2011) Therapeutic options for recurrent malignant glioma. Radiother Oncol 98: 1-14.
4. Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, et al. (2010) Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 10: 1735-1751.
5. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
6. Liang BC, Grootveld M, (2011) The importance of mitochondria in the tumourigenic phenotype: gliomas as the paradigm (review). Int J Mol Med 27: 159-171.
7. Robey RB, Hay N, (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19: 25-31.
8. Lund TM, Risa O, Sonnewald U, Schousboe A, Waagepetersen HS, (2009) Availability of neurotransmitter glutamate is diminished when beta-hydroxybutyrate replaces glucose in cultured neurons. J Neurochem 110: 80-91.
9. Wallace DC, Fan W, Procaccio V, (2010) Mitochondrial energetics and therapeutics. Annu Rev Pathol 5:297-348: 297-348.
10. Samala R, Klein J, Borges K, (2011) The ketogenic diet changes metabolite levels in hippocampal extracellular fluid. Neurochem Int 58: 5-8.
11. Schiff M, Benit P, Coulibaly A, Loublier S, El-Khoury R, et al. (2011) Mitochondrial response to controlled nutrition in health and disease. Nutr Rev 69: 65-75.
12. Eloqayli H, Melo TM, Haukvik A, Sonnewald U, (2011) [2,4-(13)C]beta-hydroxybutyrate metabolism in astrocytes and C6 glioblastoma cells. Neurochem Res 36: 1566-1573.
13. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, et al. (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7: 74.
14. Mukherjee P, Abate LE, Seyfried TN, (2004) Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10: 5622-5629.
15. Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN, (2002) Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 86: 1615-1621.
16. Mulrooney TJ, Marsh J, Urits I, Seyfried TN, Mukherjee P, (2011) Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS ONE 6: e18085.
17. Baranano KW, Hartman AL, (2008) The ketogenic diet: uses in epilepsy and other neurologic illnesses. Curr Treat Options Neurol 10: 410-419.
18. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, et al. (2010) Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. Nutrition and Metabolism 7: 33-53.
19. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, et al. (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4:5: 5.
20. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P, (2003) Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89: 1375-1382.
21. Seyfried TN, Mukherjee P, (2005) Targeting energy metabolism in brain cancer: review and hypothesis. Nutrition and Metabolism 2: 30-38.
22. Maurer GD, Brucker DP, Bahr O, Harter PN, Hattingen E, et al. (2011) Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer 11:315: 315.
23. Skinner R, Trujillo A, Ma X, Beierle EA, (2009) Ketone bodies inhibit the viability of human neuroblastoma cells. J Pediatr Surg 44: 212-216.
24. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, et al. (2010) Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9: 3506-3514.
25. Seyfried TN, Shelton LM, Mukherjee P, (2010) Does the existing standard of care increase glioblastoma energy metabolism? Lancet Oncol 11: 811-813.
26. Yamada M, Tomida A, Yun J, Cai B, Yoshikawa H, et al. (1999) Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 44: 59-64.
27. Dwarakanath B, Jain V, (2009) Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 5: 581-585.
28. Marsh J, Mukherjee P, Seyfried TN, (2008) Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet. Nutr Metab (Lond) 5:33: 33.
29. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, et al. (2004) 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34.
30. Ralser M, Wamelink MM, Struys EA, Joppich C, Krobitsch S, et al. (2008) A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc Natl Acad Sci U S A 105: 17807-17811.
31. Gupta S, Farooque A, Adhikari JS, Singh S, Dwarakanath BS, (2009) Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. J Cancer Res Ther 5 (Suppl 1): S16-S20.
32. Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, et al. (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 12: 434-443.
33. Li HF, Kim JS, Waldman T, (2009) Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4: 43.
34. Nebeling LC, Lerner E, (1995) Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 95: 693-697.
35. Nebeling LC, Miraldi F, Shurin SB, Lerner E, (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14: 202-208.
36. Abdelwahab MG, Sankar T, Preul MC, Scheck AC, (2011) Intracranial Implantation with Subsequent In Vivo Bioluminescent Imaging of Murine Gliomas. JOVE 57: e3403.
37. Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, et al. (2006) The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 12: 4730-4737.
38. Jouanneau E, Poujol D, Gulia S, Le MI, Blay JY, et al. (2006) Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 55: 254-267.